(Q33899917)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

main subject

phase II clinical trial

0 references

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

7

K Trinkaus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

R T Naismith

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

L Piccio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

J A Lyons

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

J Lauber

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

N T Tutlam

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

B J Parks

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

S K Song

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

1860-1867

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

4 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Nephrogenic systemic fibrosis: risk factors and incidence estimation.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

B cells and antibodies in CNS demyelinating disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Humoral immunity due to long-lived plasma cells.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Immunoglobulin-containing cells in multiple-sclerosis plaques

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882224

B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo

29 October 2018

1 reference

12 December 2020

Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study

1 reference

12 December 2020

Oligoclonal band number as a marker for prognosis in multiple sclerosis

1 reference

12 December 2020

Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions

1 reference

12 December 2020

Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown

1 reference

12 December 2020

10.1212/WNL.0B013E3181E24373

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20530322%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference